PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808953
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808953
Bioprosthetics Market size was valued at US$ 5,948 Million in 2024, expanding at a CAGR of 4.80% from 2025 to 2032.
Bioprosthetics is the use of biological materials in the manufacture of prosthetic devices. These devices are usually intended to replace or restore the functionality of damaged or missing body parts. Unlike traditional prosthetics, which are typically made of synthetic materials such as plastics or metals, bioprosthetics incorporate natural elements such as tissues or biomaterials to better mimic the function and structure of human body parts.
Bioprosthetics Market- Market Dynamics
Advances in regenerative medicine approaches
Rapid advances in regenerative medicine are driving innovation in bioprosthetics, particularly stem cell therapy and tissue engineering. These techniques enable the creation of bioprosthetic devices that closely resemble natural tissues, thereby improving integration, functionality, and long-term patient outcomes. For instance, in October 2024, researchers successfully used stem cell-derived therapies to treat age-related macular degeneration, significantly improving patients' vision. This breakthrough demonstrates the potential of regenerative approaches for developing bioprosthetic solutions that restore function and improve quality of life. As regenerative medicine advances, it is expected to play an important role in improving the performance and longevity of bioprosthetic implants, thereby driving market growth.
Bioprosthetics Market- Key Insights
Our research analyst estimates that the global market will grow at a CAGR of approximately 4.80% between 2025 and 2032.
Based on Product segmentation, the allograft segment dominates the market in 2025.
According to the application segment, Plastic surgery and wound healing are expected to experience significant CAGR growth during the forecast period.
North America is anticipated to lead the market in 2025.
The Global Bioprosthetics Market is segmented on the basis of Product, Application, and Region.
The market is divided into two categories based on Product: Allograft, and Xenograft. The allograft segment will dominate the market in 2025, owing to an increasing geriatric population and advances in allograft procedures. An allograft is a tissue or organ transplant from one individual to another of the same species. The world's aging population is contributing to an increase in CVD, necessitating tissue repair. The allograft prosthesis stands out for its excellent implant survival and functional performance, which improves long-term outcomes. For instance, Artivion, Inc.'s CryoValve AORTIC ALLOGRAFT includes a complete aortic root as well as the attached anterior mitral leaflet, providing several surgical implantation options.
The market is divided into two categories based on application: Cardiovascular, and Plastic surgery & wound healing. The plastic surgery and wound healing segment is expected to grow at a significant CAGR during the forecast period, owing to increased demand for minimally invasive surgery and technological advancement. According to the American Society of Plastic Surgeons (ASPS), overall cosmetic procedures performed on men increased by 6%. Furthermore, implementing minimally invasive techniques is having a positive impact on segment growth. Furthermore, the 2023 ASPS Procedural Statistics show that overall growth in cosmetic surgery procedures has increased by 5% per year.
Bioprosthetics Market- Geographical Insights
In 2025, North America is expected to dominate the market. Factors driving this growth include rising cardiovascular disease rates and established healthcare facilities in the region. According to the Centers for Disease Control and Prevention, cardiovascular disease (CVD) remains a major public health concern in the United States, with one person dying from it every 33 seconds. This alarming statistic highlights the need for better bioprosthetic heart valve options in the cardiovascular sector. The U.S. market has significantly contributed to growth in North America. This is due to rising heart disease, increased healthcare spending, and key biopharma companies in the country. Furthermore, favorable reimbursement policies and significant R&D investments are expected to accelerate market growth.
The Asia Pacific region is expected to have the fastest CAGR during the forecast period. This rapid growth is driven by increased awareness of alternative treatments, rapidly developing healthcare infrastructure, and increased engagement in research and development in developing countries like India and China. Government initiatives in these countries aim to improve healthcare accessibility and quality, which supports regional growth potential. China's Healthy China 2030 plan aims to improve health and promote longevity. This may lead to increased adoption of advanced medical technologies, such as bioprosthetics.
The bioprosthetics market is highly competitive, driven by technological innovation, material advancements, and rising demand for minimally invasive procedures. LeMaitre Vascular, Inc., Braile Biomedica, Medtronic, Rua Life Sciences Plc (Aortech International Plc.), and LivaNova PLC (Sorin Group) dominate the market with a diverse portfolio of bioprosthetic heart valves and vascular grafts. These companies compete by investing in R&D, making strategic acquisitions, and expanding globally to strengthen their market position. New companies and startups are also entering the market with innovative tissue-engineered implants and personalized bioprosthetic solutions. The growing use of transcatheter aortic valve replacement (TAVR), favorable regulatory approvals, and rising prevalence of cardiovascular and orthopedic conditions are increasing competition and accelerating innovation in the industry.
In December 2024, Meril Life Sciences, an Indian medical equipment company, recently introduced the Myval Octapro transcatheter heart valve (THV), which has received CE mark approval for transcatheter aortic valve replacement (TAVR).